Oncopeptides AB (publ) (ONPPF)
USD 0.27
(0.0%)
USD 0.27
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 289.74 Million SEK | -17.41% |
| 2022 | 357.69 Million SEK | -75.93% |
| 2021 | 1.48 Billion SEK | -6.61% |
| 2020 | 1.59 Billion SEK | 115.21% |
| 2019 | 739.39 Million SEK | 76.34% |
| 2018 | 419.3 Million SEK | 69.33% |
| 2017 | 247.61 Million SEK | 116.3% |
| 2016 | 114.48 Million SEK | 114.59% |
| 2015 | 53.34 Million SEK | 61.13% |
| 2014 | 33.1 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 80.47 Million SEK | 7.52% |
| 2024 Q1 | 73.9 Million SEK | -11.7% |
| 2023 Q2 | 88.35 Million SEK | 19.64% |
| 2023 Q3 | 41.99 Million SEK | -52.47% |
| 2023 Q1 | 73.85 Million SEK | -26.95% |
| 2023 Q4 | 83.7 Million SEK | 99.3% |
| 2023 FY | 295.42 Million SEK | -17.41% |
| 2022 Q1 | 98.86 Million SEK | -71.73% |
| 2022 FY | 357.69 Million SEK | -75.93% |
| 2022 Q2 | 69.84 Million SEK | -29.36% |
| 2022 Q4 | 101.1 Million SEK | 13.79% |
| 2022 Q3 | 88.85 Million SEK | 27.22% |
| 2021 Q4 | 349.74 Million SEK | -3.28% |
| 2021 FY | 1.48 Billion SEK | -6.61% |
| 2021 Q1 | 366.35 Million SEK | -28.39% |
| 2021 Q2 | 408.38 Million SEK | 11.47% |
| 2021 Q3 | 361.59 Million SEK | -11.46% |
| 2020 Q4 | 511.57 Million SEK | 33.4% |
| 2020 Q3 | 383.49 Million SEK | -3.97% |
| 2020 Q1 | 296.87 Million SEK | 21.55% |
| 2020 FY | 1.59 Billion SEK | 115.21% |
| 2020 Q2 | 399.33 Million SEK | 34.51% |
| 2019 Q3 | 189.59 Million SEK | 10.4% |
| 2019 FY | 739.39 Million SEK | 76.34% |
| 2019 Q4 | 244.24 Million SEK | 28.82% |
| 2019 Q2 | 171.73 Million SEK | 40.85% |
| 2019 Q1 | 121.93 Million SEK | 9.64% |
| 2018 Q1 | 68.45 Million SEK | 2.62% |
| 2018 FY | 419.3 Million SEK | 69.33% |
| 2018 Q4 | 111.21 Million SEK | 7.99% |
| 2018 Q3 | 102.98 Million SEK | -28.02% |
| 2018 Q2 | 143.07 Million SEK | 109.02% |
| 2017 Q4 | 66.7 Million SEK | 29.34% |
| 2017 Q1 | 62.08 Million SEK | 21.52% |
| 2017 Q2 | 67.26 Million SEK | 8.34% |
| 2017 Q3 | 51.57 Million SEK | -23.32% |
| 2017 FY | 247.61 Million SEK | 116.3% |
| 2016 Q1 | 15.24 Million SEK | 0.0% |
| 2016 Q2 | 23.48 Million SEK | 54.05% |
| 2016 Q4 | 51.08 Million SEK | 107.11% |
| 2016 FY | 114.48 Million SEK | 114.59% |
| 2016 Q3 | 24.66 Million SEK | 5.04% |
| 2015 FY | 53.34 Million SEK | 61.13% |
| 2014 FY | 33.1 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Agentix Corp. | 1.37 Million USD | -21022.27% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -5646.598% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -7836.709% |
| Biomind Labs Inc. | 994.18 Thousand USD | -29044.161% |
| ContraFect Corporation | 56.88 Million USD | -409.318% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -21497.934% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -10927.348% |
| CSL Limited | 3.44 Billion USD | 91.599% |
| CytoDyn Inc. | 18.05 Million USD | -1504.53% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -880.428% |
| GB Sciences, Inc. | 1.42 Million USD | -20297.336% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -15441.228% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -8409.48% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -74276.614% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -131556.049% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -404.432% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -69637.821% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -19191.976% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -31274.43% |
| Skye Bioscience, Inc. | 13.54 Million USD | -2038.734% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -677.723% |
| SQZ Biotechnologies Company | 85.61 Million USD | -238.413% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -14042.885% |
| Zenith Capital Corp. | 8.94 Million USD | -3139.919% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -233.866% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -9835.619% |
| Mesoblast Limited | 5.9 Million USD | -4809.285% |
| Marizyme, Inc. | 19.23 Million USD | -1405.969% |
| Genus plc | 147.7 Million USD | -96.172% |
| Pharming Group N.V. | 225.49 Million USD | -28.496% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -3374.589% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -19493.955% |
| IMV Inc. | 37.7 Million USD | -668.369% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -10283.833% |
| MultiCell Technologies, Inc. | 567.42 USD | -51063662.292% |
| ONE Bio Corp. | 6.44 Million USD | -4396.444% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -237.13% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -1072.349% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -16365.853% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -4212.97% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 1159084.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -1709.755% |
| Alpha Cognition Inc. | 9.7 Million USD | -2885.348% |
| Enzolytics Inc. | 2.17 Million USD | -13194.107% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 81.106% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -27653.448% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -11947.981% |
| Genscript Biotech Corporation | 825.34 Million USD | 64.894% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -5791.646% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -110605.853% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -11700.757% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -168839.239% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -14983.82% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -3200.356% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -6472.183% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 3.74 Million USD | -7633.945% |
| Helix BioMedix, Inc. | 1.97 Million USD | -14592.749% |
| EV Biologics, Inc. | 531.96 Thousand USD | -54367.424% |
| Q BioMed Inc. | 3.43 Million USD | -8331.113% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -2566.292% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -191.7% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | -1161.147% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -15689.155% |
| HST Global, Inc. | 140.9 Thousand USD | -205529.245% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -21596.815% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -25657.261% |
| Halberd Corporation | 74.84 Thousand USD | -387043.582% |
| Resverlogix Corp. | 12.71 Million USD | -2179.311% |
| Cell Source, Inc. | 4.32 Million USD | -6598.794% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -18245.844% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 7.31 Million USD | -3863.55% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -1663099.587% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -11646.01% |
| Kadimastem Ltd | 2.41 Million USD | -11922.097% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -6736.189% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -159552.864% |
| LadRx Corporation | 3.81 Million USD | -7501.309% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -31274.43% |
| Affymax, Inc. | 39.38 Million USD | -635.657% |
| Itoco Inc. | 919.14 Thousand USD | -31423.495% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -25793.298% |
| Mobile Lads Corp. | 554.54 Thousand USD | -52149.227% |
| International Stem Cell Corporation | 5.27 Million USD | -5396.983% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.82 Million USD | -7484.682% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -1151101.875% |
| Qrons Inc. | 643.67 Thousand USD | -44914.192% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -20307.637% |
| SYBLEU INC | 160.87 Thousand USD | -180005.174% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -12893.799% |
| Rebus Holdings, Inc. | 664 Thousand USD | -43536.446% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -15852.365% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -550308.419% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -1424203.2% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -698.947% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -17807.664% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -39276.491% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -9213.597% |
| Neutra Corp. | 243.82 Thousand USD | -118735.539% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1559.77% |
| PureTech Health plc | 144.59 Million USD | -100.382% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -1314.093% |
| IXICO plc | 4.7 Million USD | -6055.641% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -3193.691% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -146.073% |
| CSL Limited | 3.89 Billion USD | 92.557% |
| Cellectis S.A. | 97.32 Million USD | -197.725% |